Suppr超能文献

比马前列素与丙酸氯倍他索治疗斑秃的前瞻性非随机开放标签临床试验

Bimatoprost versus Clobetasol Propionate in Scalp Alopecia Areata: A Prospective Non-Randomized Open-Label Clinical Trial.

作者信息

Bhusal Mohan, Bhattarai Sabina, Thapa Binita, Shrestha Prashanna R, Sagar G C

机构信息

Department of Dermatology, Nepal Medical College, Kathmandu, Nepal.

Lavana Skin and Hair Clinic, Kathmandu, Nepal.

出版信息

Indian Dermatol Online J. 2023 Mar 3;14(2):221-225. doi: 10.4103/idoj.idoj_299_22. eCollection 2023 Mar-Apr.

Abstract

BACKGROUND

Alopecia areata (AA) is one of the most common forms of alopecia presenting to the dermatology out patient department (OPD) worldwide as well as in Nepal. It is mostly diagnosed clinically. Treatment depends on the extent, location, and severity of the condition. Various treatment options available are topical, intralesional, and oral medications. Bimatoprost is a relatively newer treatment modality in AA.

AIM AND OBJECTIVE

To compare the efficacy and safety of topical bimatoprost 0.01% solution versus clobetasol propionate 0.05% cream in scalp AA.

MATERIALS AND METHODS

A total of 50 patients attending the dermatology OPD of a tertiary hospital between March 2018 and February 2019 were included in this prospective non-randomized open-label clinical trial. Patients were divided into two groups i.e., Group A- topical bimatoprost solution 0.01% and Group B- topical clobetasol propionate cream 0.05%, and followed up at weeks 4, 8, and 12. The improvement was analyzed subjectively by hair regrowth and objectively by Severity of Alopecia Tool (SALT) score. Side effects, nature of terminal hair and onset of initial response were also recorded.

RESULTS

Out of 50 patients, 27 were males and 23 were females with a mean age of 28.5 ± 9.34 years and mean duration of disease of 18.67 ± 46.1 weeks. Hair regrowth rate and reduction in SALT score from baseline were seen more in clobetasol group compared to bimatoprost ( = 0.282 and = 0.246, respectively). Side effects were seen more in the clobetasol group compared to bimatoprost group ( = 0.002). Onset of cosmetically acceptable hair regrowth was seen earlier in the bimatoprost group ( = 0.017) and also the nature of regrown hairs was more pigmented in bimatoprost group ( = 0.024).

CONCLUSIONS

There is no significant difference in hair regrowth between clobetasol and bimatoprost in the treatment of AA on scalp at the end of 12 weeks, although bimatoprost has an advantage of lesser side effects, more rapid response and growth of more pigmented hairs.

摘要

背景

斑秃(AA)是皮肤科门诊最常见的脱发形式之一,在全球以及尼泊尔均是如此。其大多通过临床诊断。治疗取决于病情的范围、部位和严重程度。现有的各种治疗选择包括局部用药、皮损内注射和口服药物。比马前列素是治疗斑秃相对较新的一种治疗方式。

目的

比较0.01%比马前列素溶液与0.05%丙酸氯倍他索乳膏治疗头皮斑秃的疗效和安全性。

材料与方法

本前瞻性非随机开放标签临床试验纳入了2018年3月至2019年2月期间在一家三级医院皮肤科门诊就诊的50例患者。患者被分为两组,即A组——0.01%比马前列素溶液组和B组——0.05%丙酸氯倍他索乳膏组,并在第4周、第8周和第12周进行随访。通过毛发再生主观分析改善情况,通过脱发严重程度工具(SALT)评分客观分析改善情况。还记录了副作用、终毛性质和初始反应的发生时间。

结果

50例患者中,男性27例,女性23例,平均年龄28.5±9.34岁,平均病程18.67±46.1周。与比马前列素组相比,丙酸氯倍他索组的毛发再生率和SALT评分较基线的降低幅度更大(分别为 = 0.282和 = 0.246)。与比马前列素组相比,丙酸氯倍他索组的副作用更多( = 0.002)。比马前列素组出现美容上可接受的毛发再生更早( = 0.017),且比马前列素组再生毛发的性质色素沉着更多( = 0.024)。

结论

在治疗头皮斑秃12周结束时,丙酸氯倍他索和比马前列素在毛发再生方面无显著差异,尽管比马前列素有副作用较少、反应更快以及再生毛发色素沉着更多的优势。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8b4/10115310/c2065e7a4b3c/IDOJ-14-221-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验